Ignite Creation Date:
2025-12-24 @ 6:33 PM
Ignite Modification Date:
2026-04-09 @ 6:57 AM
Study NCT ID:
NCT05431257
Status:
RECRUITING
Last Update Posted:
2022-06-24
First Post:
2022-06-01
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Azacitidine in Combination With Low Dose Intensity Venetoclax in Patients With AML Incl. Explorative AML Profiling
Sponsor:
Rigshospitalet, Denmark
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-05-24
Start Date Type:
ACTUAL
Primary Completion Date:
2031-09-01
Primary Completion Date Type:
ESTIMATED
Completion Date:
2031-09-01
Completion Date Type:
ESTIMATED
First Submit Date:
2022-06-01
First Submit QC Date:
None
Study First Post Date:
2022-06-24
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-06-21
Last Update Post Date:
2022-06-24
Last Update Post Date Type:
ACTUAL